HK1052338A1 - Compounds for modulating the rage receptor - Google Patents
Compounds for modulating the rage receptorInfo
- Publication number
- HK1052338A1 HK1052338A1 HK03103492A HK03103492A HK1052338A1 HK 1052338 A1 HK1052338 A1 HK 1052338A1 HK 03103492 A HK03103492 A HK 03103492A HK 03103492 A HK03103492 A HK 03103492A HK 1052338 A1 HK1052338 A1 HK 1052338A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- compounds
- rage
- diseases
- development
- end products
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/40—Radicals substituted by oxygen atoms
- C07D307/42—Singly bound oxygen atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20734300P | 2000-05-30 | 2000-05-30 | |
US09/799,317 US6613801B2 (en) | 2000-05-30 | 2001-03-05 | Method for the synthesis of compounds of formula I and their uses thereof |
PCT/US2001/017251 WO2001092210A1 (en) | 2000-05-30 | 2001-05-25 | Compounds for modulating the rage receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1052338A1 true HK1052338A1 (en) | 2003-09-11 |
Family
ID=26902168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK03103492A HK1052338A1 (en) | 2000-05-30 | 2003-05-16 | Compounds for modulating the rage receptor |
Country Status (12)
Country | Link |
---|---|
US (4) | US6613801B2 (es) |
EP (2) | EP1284959B1 (es) |
JP (1) | JP4451058B2 (es) |
AT (2) | ATE531688T1 (es) |
AU (2) | AU780368B2 (es) |
CA (2) | CA2379695C (es) |
DE (1) | DE60112079T2 (es) |
DK (1) | DK1284959T3 (es) |
ES (2) | ES2373557T3 (es) |
HK (1) | HK1052338A1 (es) |
MX (1) | MXPA02001099A (es) |
WO (1) | WO2001092210A1 (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6613801B2 (en) * | 2000-05-30 | 2003-09-02 | Transtech Pharma, Inc. | Method for the synthesis of compounds of formula I and their uses thereof |
US20050026811A1 (en) * | 2003-05-20 | 2005-02-03 | Mjalli Adnan M. M. | Rage antagonists as agents to reverse amyloidosis and diseases associated therewith |
DE60135752D1 (en) * | 2000-07-06 | 2008-10-23 | Array Biopharma Inc | Tyrosinderivate als phosphatase inhibitoren |
CN1494425B (zh) * | 2001-03-05 | 2011-12-07 | 特兰斯泰克制药公司 | 用作治疗剂的羧酰胺衍生物 |
JP2004523565A (ja) * | 2001-03-05 | 2004-08-05 | トランス テック ファーマ,インコーポレイテッド | 治療因子としてのベンゾイミダゾール誘導体 |
AU2002358771B2 (en) * | 2001-12-19 | 2009-04-23 | Alcedo Biotech Gmbh | Use of HMGB proteins and nucleic acids that code therefor |
CN101597262A (zh) * | 2002-03-05 | 2009-12-09 | 特兰斯泰克制药公司 | 抑制配体与高级糖化终产物受体相互作用的单和双环吡咯衍生物 |
NZ536665A (en) * | 2002-06-11 | 2006-11-30 | Wyeth Corp | Use of substituted phenylsulfonamide as inhibitors of beta amyloid production |
GB0220216D0 (en) * | 2002-08-30 | 2002-10-09 | Novo Pharmaceuticals De Ltd | Compounds and their use |
WO2004079368A2 (en) | 2003-03-08 | 2004-09-16 | Auvation Ltd | Markers for colorectal cancer |
JP4607950B2 (ja) * | 2004-03-18 | 2011-01-05 | トランス テック ファーマ,インコーポレイテッド | 蛍光偏光アッセイ |
WO2006012415A2 (en) * | 2004-07-20 | 2006-02-02 | Critical Therapeutics, Inc. | Rage protein derivatives |
CN101014360A (zh) * | 2004-08-03 | 2007-08-08 | 埃米斯菲尔技术公司 | 抗糖尿病口服胰岛素-双胍组合物 |
WO2006017647A1 (en) | 2004-08-03 | 2006-02-16 | Transtech Pharma, Inc. | Rage fusion proteins and methods of use |
EP1776459A1 (en) * | 2004-08-03 | 2007-04-25 | Transtech Pharma, Inc. | Rage fusion proteins and methods of use |
US20060084145A1 (en) | 2004-09-27 | 2006-04-20 | Anderson Glenn M | sRAGE mimetibody, compositions, methods and uses |
WO2006119510A2 (en) * | 2005-05-04 | 2006-11-09 | Receptor Biologix, Inc. | Isoforms of receptor for advanced glycation end products (rage) and methods of identifying and using same |
WO2007044309A2 (en) * | 2005-10-05 | 2007-04-19 | Vasix Corporation | Device and method for inhibiting age complex formation |
US20080295194A1 (en) * | 2007-04-02 | 2008-11-27 | Miami University | Transgenic plants with enhanced characteristics |
US20100254983A1 (en) * | 2007-06-07 | 2010-10-07 | Ann Marie Schmidt | Uses of rage antagonists for treating obesity and related diseases |
PL2158210T3 (pl) | 2007-06-14 | 2016-08-31 | Galactica Pharmaceuticals Inc | Białka fuzyjne RAGE |
RU2011142230A (ru) | 2009-04-20 | 2013-05-27 | Пфайзер Инк. | Контроль гликозилирования белка и композиции и способы, касающиеся этого |
TWI517850B (zh) | 2009-09-30 | 2016-01-21 | Vtv治療有限責任公司 | 經取代之咪唑衍生物及其使用方法 |
US8431575B2 (en) * | 2010-02-18 | 2013-04-30 | Transtech Pharma, Inc. | Phenyl-heteroaryl derivatives and methods of use thereof |
BR112012027427A2 (pt) * | 2010-04-26 | 2015-09-15 | Nestec Sa | composições nutritivas e métodos para a mudança da nutrição parenteral para a nutrição enteral |
US9717710B2 (en) | 2012-10-05 | 2017-08-01 | Vtv Therapeutics Llc | Treatment of mild and moderate Alzheimer's disease |
WO2016201368A1 (en) | 2015-06-10 | 2016-12-15 | The Broad Institute Inc. | Antibodies, compounds and screens for identifying and treating cachexia or pre-cachexia |
WO2019190823A1 (en) | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
WO2019190822A1 (en) | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
WO2020076668A1 (en) | 2018-10-10 | 2020-04-16 | Vtv Therapeutics Llc | Metabolites of [3-(4-{2-butyl-l-[4-(4-chloro-phenoxy)-phenyl]-lh-imidazol-4-yl } -phen ox y)-prop yl] -diethyl-amine |
CN111825576B (zh) * | 2020-07-21 | 2023-10-27 | 安徽东凯生物科技股份有限公司 | 一种氨基酸制备方法 |
CN117843513A (zh) * | 2024-03-07 | 2024-04-09 | 深圳创元生物医药科技有限公司 | 一种(S)-3-Carboxytyrosine的制备方法 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
IL55573A0 (en) | 1977-10-03 | 1978-12-17 | Erba Carlo Spa | Substituted n-(ss-alkoxy-ethyl)-n-(4-phenoxybenzyl)-dichloroacetamides and process for their preparation |
US4356108A (en) | 1979-12-20 | 1982-10-26 | The Mead Corporation | Encapsulation process |
US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
US5585344A (en) | 1984-03-19 | 1996-12-17 | The Rockefeller University | Liver-derived receptors for advanced glycosylation endproducts and uses thereof |
US5202424A (en) | 1984-03-19 | 1993-04-13 | The Rockefeller University | Mesangial cell-derived receptors for advanced glycosylation endproducts and uses thereof |
US4873313A (en) | 1985-01-18 | 1989-10-10 | Beckman Research Institute Of City Of Hope | Specific hybridoma cell line and monocolonal antibodies produced from such specific hybridoma cell line and method of using such monoclonal antibodies to detect carcinoembryonic antigens |
US4963539A (en) * | 1987-09-10 | 1990-10-16 | E. R. Squibb & Sons, Inc. | Phosphonate and phosphonamide endopeptidase inhibitors |
US5153226A (en) * | 1989-08-31 | 1992-10-06 | Warner-Lambert Company | Acat inhibitors for treating hypocholesterolemia |
AU687449B2 (en) | 1993-10-01 | 1998-02-26 | Aventis Inc. | Inhibitors of beta-amyloid protein production |
GB9409150D0 (en) * | 1994-05-09 | 1994-06-29 | Black James Foundation | Cck and gastrin receptor ligands |
US5597845A (en) | 1994-06-20 | 1997-01-28 | Merrell Pharmaceuticals Inc. | Substituted alkyldiamine derivatives |
US5939526A (en) | 1995-03-21 | 1999-08-17 | Ludwig Institute For Cancer Research | Isolated RAGE-1 derived peptides which complex with HLA-B7 molecules and uses thereof |
KR100414321B1 (ko) | 1995-04-13 | 2004-02-18 | 아벤티스 파마슈티칼스 인크. | 타치키닌수용체길항활성을갖는신규한치환된피페라진유도체 |
US6228858B1 (en) | 1995-09-12 | 2001-05-08 | University Of Kansas Medical Center | Advanced glycation end-product intermediaries and post-amadori inhibition |
US5843904A (en) | 1995-12-20 | 1998-12-01 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1βconverting enzyme |
WO1997026913A1 (en) | 1996-01-26 | 1997-07-31 | The Trustees Of Columbia University In The City Of New York | A POLYPEPTIDE FROM LUNG EXTRACT WHICH BINDS AMYLOID-β PEPTIDE |
US5864018A (en) | 1996-04-16 | 1999-01-26 | Schering Aktiengesellschaft | Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor |
AU2696097A (en) | 1996-04-16 | 1997-11-07 | Schering Aktiengesellschaft | Advanced glycosylation end-product receptor peptides and uses therefor |
US5688653A (en) | 1996-06-27 | 1997-11-18 | The Picower Institute For Medical Research | 3-alkylamino-2-hydroxy-4-hydroxymethyl-2-cyclopenten-1-one advanced glycosylation endproducts and methods of use therefor |
DE69734215T2 (de) * | 1996-07-22 | 2006-06-29 | Novo Nordisk A/S | Verbindungen mit Wachstumshormon-freisetzenden Eigenschaften |
US6790443B2 (en) | 1996-11-22 | 2004-09-14 | The Trustees Of Columbia University In The City Of New York | Method for treating symptoms of diabetes |
US6555651B2 (en) | 1997-10-09 | 2003-04-29 | The Trustees Of Columbia University In The City Of New York | Ligand binding site of rage and uses thereof |
US6004958A (en) | 1997-02-05 | 1999-12-21 | Fox Chase Cancer Center | Compounds and methods for therapeutic intervention in preventing diabetic complications and procedures for assessing a diabetic's risk of developing complications and determining the efficacy of therapeutic intervention |
US6100098A (en) | 1997-02-18 | 2000-08-08 | Mcgill University | Anti-AGE IgG and uses thereof for the diagnosis of severe disease |
US7101838B2 (en) | 1997-08-05 | 2006-09-05 | The Trustees Of Columbia University In The City Of New York | Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts |
ES2281170T3 (es) | 1998-03-31 | 2007-09-16 | Vertex Pharmaceuticals Incorporated | Inhibidores de serina proteasas, particularmente proteasa ns3 del virus de la hepatitis c. |
US6465422B1 (en) | 1998-04-17 | 2002-10-15 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting tumor invasion or spreading in a subject |
US6753150B2 (en) | 1998-10-05 | 2004-06-22 | The Trustees Of Columbia University In The City Of New York | Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage |
EP1121454B1 (en) | 1998-10-06 | 2007-11-14 | The Trustees of Columbia University in the City of New York | Extracellular novel rage binding protein (en-rage) and uses thereof |
US20050026811A1 (en) * | 2003-05-20 | 2005-02-03 | Mjalli Adnan M. M. | Rage antagonists as agents to reverse amyloidosis and diseases associated therewith |
US6613801B2 (en) * | 2000-05-30 | 2003-09-02 | Transtech Pharma, Inc. | Method for the synthesis of compounds of formula I and their uses thereof |
US6825164B1 (en) * | 2000-08-14 | 2004-11-30 | The Trustees Of Columbia University In The City Of New York | Method to increase cerebral blood flow in amyloid angiopathy |
-
2001
- 2001-03-05 US US09/799,317 patent/US6613801B2/en not_active Expired - Fee Related
- 2001-05-25 DE DE60112079T patent/DE60112079T2/de not_active Expired - Lifetime
- 2001-05-25 DK DK01939581T patent/DK1284959T3/da active
- 2001-05-25 JP JP2002500825A patent/JP4451058B2/ja not_active Expired - Fee Related
- 2001-05-25 CA CA002379695A patent/CA2379695C/en not_active Expired - Fee Related
- 2001-05-25 AT AT05076535T patent/ATE531688T1/de active
- 2001-05-25 EP EP01939581A patent/EP1284959B1/en not_active Expired - Lifetime
- 2001-05-25 CA CA002599562A patent/CA2599562A1/en not_active Abandoned
- 2001-05-25 WO PCT/US2001/017251 patent/WO2001092210A1/en active IP Right Grant
- 2001-05-25 MX MXPA02001099A patent/MXPA02001099A/es active IP Right Grant
- 2001-05-25 ES ES05076535T patent/ES2373557T3/es not_active Expired - Lifetime
- 2001-05-25 AT AT01939581T patent/ATE299860T1/de active
- 2001-05-25 EP EP05076535A patent/EP1642888B1/en not_active Expired - Lifetime
- 2001-05-25 ES ES01939581T patent/ES2243506T3/es not_active Expired - Lifetime
- 2001-05-25 AU AU65083/01A patent/AU780368B2/en not_active Ceased
-
2003
- 2003-05-16 HK HK03103492A patent/HK1052338A1/xx not_active IP Right Cessation
- 2003-07-01 US US10/611,741 patent/US7067554B2/en not_active Expired - Fee Related
-
2005
- 2005-02-02 AU AU2005200425A patent/AU2005200425B2/en not_active Ceased
-
2006
- 2006-01-12 US US11/331,256 patent/US20060189578A1/en not_active Abandoned
- 2006-02-27 US US11/362,993 patent/US20060148760A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1642888B1 (en) | 2011-11-02 |
MXPA02001099A (es) | 2004-04-05 |
EP1284959B1 (en) | 2005-07-20 |
JP4451058B2 (ja) | 2010-04-14 |
AU2005200425A1 (en) | 2005-02-24 |
CA2379695C (en) | 2007-11-27 |
ES2373557T3 (es) | 2012-02-06 |
DE60112079T2 (de) | 2006-06-01 |
CA2599562A1 (en) | 2001-12-06 |
US6613801B2 (en) | 2003-09-02 |
AU780368B2 (en) | 2005-03-17 |
EP1284959A1 (en) | 2003-02-26 |
AU6508301A (en) | 2001-12-11 |
US20020006957A1 (en) | 2002-01-17 |
DK1284959T3 (da) | 2005-11-21 |
ATE299860T1 (de) | 2005-08-15 |
US20060148760A1 (en) | 2006-07-06 |
US20060189578A1 (en) | 2006-08-24 |
ATE531688T1 (de) | 2011-11-15 |
DE60112079D1 (de) | 2005-08-25 |
WO2001092210A1 (en) | 2001-12-06 |
CA2379695A1 (en) | 2001-12-06 |
AU2005200425B2 (en) | 2009-01-15 |
US7067554B2 (en) | 2006-06-27 |
US20040097407A1 (en) | 2004-05-20 |
ES2243506T3 (es) | 2005-12-01 |
JP2004519416A (ja) | 2004-07-02 |
EP1642888A1 (en) | 2006-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1052338A1 (en) | Compounds for modulating the rage receptor | |
WO2002070473A3 (en) | Carboxamide derivatives as therapeutic agents | |
WO2003075921A3 (en) | Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage | |
WO2001009118A3 (en) | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement | |
ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
BRPI0518322A2 (pt) | composiÇço, kit, e, mÉtodos para tratar uma condiÇço, para reverter um efeito no sistema nervoso central de um agente, para tratar um animal de dor, e para controlar dor crânica | |
WO2003099771A3 (en) | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | |
WO2005007652A3 (en) | Substituted quinolin-4-ylamine analogues | |
WO2005007648A3 (en) | Biaryl piperazinyl-pyridine analogues | |
EP1262177A3 (en) | Medical use of thyromimetic compounds to treat hair loss and compositions | |
BRPI0313792B8 (pt) | utilização de proteína de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento | |
WO2003092617A3 (en) | Combinations for the treatment of inflammatory skin disorders | |
WO2002058636A3 (en) | Novel cannabimimetic ligands | |
WO2004110151A8 (en) | Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments | |
WO2003017939A3 (en) | Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment | |
WO2002098362A3 (en) | Use of rank antagonists to treat cancer | |
AU2002222180A1 (en) | The use of ppar-gamma agonists for treating diseases characterised by neuron degeneration, neuron injury or impaired pasticity | |
PT1237562E (pt) | Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas | |
WO2002087503A3 (en) | Compositions and methods for treating colorectal polyps and cancer | |
WO2004056768A3 (en) | Use of substituted 2,5-diamidoindoles for the treatment of urological diseases | |
ATE548048T1 (de) | Oncomodulin zur behandlung von neurologishen erkrankungen | |
WO2003080800A3 (en) | Prevention and treatment of disease using angiogenesis-and/or tumor antigens | |
WO2003028536A3 (en) | Methods for diagnosing and treating heart disease | |
DE69720410D1 (de) | Therapeutisches Mittel zur Behandlung hartnäckiger Hundedermatitis | |
WO2000043028A3 (en) | Method of treating chronic cardiac disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20140525 |